217 related articles for article (PubMed ID: 33713429)
21. Cell-free DNA analysis for detection of MYD88
Demos MG; Hunter ZR; Xu L; Tsakmaklis N; Kofides A; Munshi M; Liu X; Guerrera ML; Leventoff CR; White TP; Flynn CA; Meid K; Patterson CJ; Yang G; Branagan AR; Sarosiek S; Castillo JJ; Treon SP; Gustine JN
Am J Hematol; 2021 Jul; 96(7):E250-E253. PubMed ID: 33819355
[No Abstract] [Full Text] [Related]
22. Genomic Landscape of Waldenström Macroglobulinemia.
Treon SP; Xu L; Liu X; Hunter ZR; Yang G; Castillo JJ
Hematol Oncol Clin North Am; 2018 Oct; 32(5):745-752. PubMed ID: 30190014
[TBL] [Abstract][Full Text] [Related]
23. Genomic Landscape of CXCR4 Mutations in Waldenström Macroglobulinemia.
Poulain S; Roumier C; Venet-Caillault A; Figeac M; Herbaux C; Marot G; Doye E; Bertrand E; Geffroy S; Lepretre F; Nibourel O; Decambron A; Boyle EM; Renneville A; Tricot S; Daudignon A; Quesnel B; Duthilleul P; Preudhomme C; Leleu X
Clin Cancer Res; 2016 Mar; 22(6):1480-8. PubMed ID: 26490317
[TBL] [Abstract][Full Text] [Related]
24. Diagnostic Tools of Waldenströms Macroglobulinemia - Best Possibilities for Non-invasive and Long-term Disease Monitoring.
Growkova K; Kufová Z; Sevcikova T; Filipová J; Kascak M; Jelínek T; Grosicki S; Barchnicka A; Roziaková Ľ; Mistrík M; Simicek M; Hájek R
Klin Onkol; 2017; 30(Supplementum2):81-91. PubMed ID: 28903575
[TBL] [Abstract][Full Text] [Related]
25. Highly Sensitive Detection Method of CXCR4 Tumor Hotspot Mutations by Drop-Off Droplet Digital PCR in Patients with IgM Monoclonal Gammopathies.
Markou AN; Bagratuni T; Tsakiri C; Tserpeli V; Skourti S; Mavrianou Koutsoukou N; Papadimou A; Terpos E; Kastritis E; Lianidou E; Dimopoulos MA
J Mol Diagn; 2023 Jul; 25(7):502-512. PubMed ID: 37088135
[TBL] [Abstract][Full Text] [Related]
26. Working Toward a Genomic Prognostic Classification of Waldenström Macroglobulinemia: C-X-C Chemokine Receptor Type 4 Mutation and Beyond.
Magierowicz M; Tomowiak C; Leleu X; Poulain S
Hematol Oncol Clin North Am; 2018 Oct; 32(5):753-763. PubMed ID: 30190015
[TBL] [Abstract][Full Text] [Related]
27. The genomic landscape of Waldenstrom macroglobulinemia is characterized by highly recurring MYD88 and WHIM-like CXCR4 mutations, and small somatic deletions associated with B-cell lymphomagenesis.
Hunter ZR; Xu L; Yang G; Zhou Y; Liu X; Cao Y; Manning RJ; Tripsas C; Patterson CJ; Sheehy P; Treon SP
Blood; 2014 Mar; 123(11):1637-46. PubMed ID: 24366360
[TBL] [Abstract][Full Text] [Related]
28. Detection of MYD88 L265P and WHIM-like CXCR4 mutation in patients with IgM monoclonal gammopathy related disease.
Cao XX; Meng Q; Cai H; He TH; Zhang CL; Su W; Sun J; Li Y; Xu W; Zhou DB; Li J
Ann Hematol; 2017 Jun; 96(6):971-976. PubMed ID: 28280994
[TBL] [Abstract][Full Text] [Related]
29. Zanubrutinib for the treatment of Waldenström Macroglobulinemia.
Lim KJC; Tam CS
Expert Rev Hematol; 2020 Dec; 13(12):1303-1310. PubMed ID: 33297772
[No Abstract] [Full Text] [Related]
30. CXCR4 mutations affect presentation and outcomes in patients with Waldenström macroglobulinemia: A systematic review.
Castillo JJ; Moreno DF; Arbelaez MI; Hunter ZR; Treon SP
Expert Rev Hematol; 2019 Oct; 12(10):873-881. PubMed ID: 31343930
[No Abstract] [Full Text] [Related]
31. Clinical and molecular characteristics of lymphoplasmacytic lymphoma not associated with an IgM monoclonal protein: A multicentric study of the Rete Ematologica Lombarda (REL) network.
Varettoni M; Boveri E; Zibellini S; Tedeschi A; Candido C; Ferretti VV; Rizzo E; Doni E; Merli M; Farina L; Goldaniga M; Gallì A; Rattotti S; Frustaci AM; Deodato M; Bandiera L; Isimbaldi G; Uccella S; Cabras AD; Gianelli U; Baldini L; Paulli M; Arcaini L
Am J Hematol; 2019 Nov; 94(11):1193-1199. PubMed ID: 31378966
[TBL] [Abstract][Full Text] [Related]
32. Significances of MYD88
Meng Q; Cao XX; Li J
Zhongguo Yi Xue Ke Xue Yuan Xue Bao; 2017 Aug; 39(4):578-582. PubMed ID: 28877839
[TBL] [Abstract][Full Text] [Related]
33. Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia.
Treon SP; Gustine J; Meid K; Yang G; Xu L; Liu X; Demos M; Kofides A; Tsakmaklis N; Chen JG; Munshi M; Chan G; Dubeau T; Raje N; Yee A; O'Donnell E; Hunter ZR; Castillo JJ
J Clin Oncol; 2018 Sep; 36(27):2755-2761. PubMed ID: 30044692
[TBL] [Abstract][Full Text] [Related]
34. The BCL2 antagonist ABT-199 triggers apoptosis, and augments ibrutinib and idelalisib mediated cytotoxicity in CXCR4 Wild-type and CXCR4 WHIM mutated Waldenstrom macroglobulinaemia cells.
Cao Y; Yang G; Hunter ZR; Liu X; Xu L; Chen J; Tsakmaklis N; Hatjiharissi E; Kanan S; Davids MS; Castillo JJ; Treon SP
Br J Haematol; 2015 Jul; 170(1):134-8. PubMed ID: 25582069
[No Abstract] [Full Text] [Related]
35. [Exploring the detection of MYD88 mutation in patients with Waldenström macroglobulinemia by different methods and specimens].
Tao Y; Pan ZK; Wang S; Wang L; Zhao WL
Zhonghua Xue Ye Xue Za Zhi; 2022 May; 43(5):388-392. PubMed ID: 35680596
[No Abstract] [Full Text] [Related]
36. Phase 1 study of ibrutinib and the CXCR4 antagonist ulocuplumab in CXCR4-mutated Waldenström macroglobulinemia.
Treon SP; Meid K; Hunter ZR; Flynn CA; Sarosiek SR; Leventoff CR; White TP; Cao Y; Roccaro AM; Sacco A; Demos MG; Guerrera ML; Kofides A; Liu X; Xu L; Patterson CJ; Munshi M; Tsakmaklis N; Yang G; Ghobrial IM; Branagan AR; Castillo JJ
Blood; 2021 Oct; 138(17):1535-1539. PubMed ID: 34289017
[TBL] [Abstract][Full Text] [Related]
37. MYD88 L265P and CXCR4 mutations in lymphoplasmacytic lymphoma identify cases with high disease activity.
Schmidt J; Federmann B; Schindler N; Steinhilber J; Bonzheim I; Fend F; Quintanilla-Martinez L
Br J Haematol; 2015 Jun; 169(6):795-803. PubMed ID: 25819228
[TBL] [Abstract][Full Text] [Related]
38. MALT lymphoma with IgM paraprotein and bone marrow involvement mimicking Waldenström macroglobulinaemia.
Wang SC; Huang WT; Ma MC; Medeiros LJ; Chang KC
Pathology; 2019 Aug; 51(5):549-553. PubMed ID: 31202483
[No Abstract] [Full Text] [Related]
39. Mutational landscape in Waldenström macroglobulinemia evaluated using a next-generation sequencing lymphoma panel in routine clinical practice.
Østergaard S; Schejbel L; Breinholt MF; Pedersen MØ; Hammer T; Munksgaard L; Nørgaard P; Høgdall E; Gjerdrum LMR; Nielsen TH
Leuk Lymphoma; 2024 Jun; 65(6):758-767. PubMed ID: 38340359
[TBL] [Abstract][Full Text] [Related]
40. [Waldenström's macroglobulinemia and its individualized therapy options].
Szemlaky Z; Mikala G
Orv Hetil; 2017 Oct; 158(41):1604-1614. PubMed ID: 29025291
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
